This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prothena (PRTA) Down 14.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 13.33% and -7.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Is Prothena (PRTA) Up 12.6% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Prothena's (PRTA) Q4 loss was narrower than expected, while revenues missed expectations.
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 41.67% and -30.71%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Prothena (PRTA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Prothena (PRTA) Stock Options
by Zacks Equity Research
Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.
Prothena (PRTA) Down 12.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 33.33% and -2.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Prothena (PRTA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celgene (CELG) Tops Q3 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene (CELG) third-quarter revenues gain on strong sales of Otezla and Revlimid.
Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study
by Zacks Equity Research
Celgene's (CELG) efforts to expand psoriasis drug, Otezla gets a boost as the late-stage study for the indication of plaque psoriasis of the scalp meets primary endpoint.
Are Options Traders Betting on a Big Move in Prothena (PRTA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Prothena (PRTA) stock based on the movements in the options market lately.
Why Is Prothena (PRTA) Up 8.2% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Celgene Set to See Improved Results in the Second Half?
by Zacks Equity Research
After a series of pipeline setbacks, things are looking better for biotech bigwig Celgene (CELG) with positive data read-outs and an increase in guidance.
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -11.36% and 29.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?
by Zacks Equity Research
Prothena's (PRTA) Q2 results are likely to reflect pipeline updates along with progress with its restructuring plan.
Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene (CELG) reports better-than-expected results for the second-quarter, on the back of growth in Revlimid sales. The company also raises its annual guidance.
Prothena (PRTA) Down 3.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst
by Zacks Equity Research
Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.
Implied Volatility Surging for Prothena (PRTA) Stock Options
by Zacks Equity Research
Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.
Prothena Restructures Resources, to Cut Workforce by 57%
by Zacks Equity Research
Prothena announces a reduction in workforce by 57%, due to the discontinuation of lead program, NEOD001.